CN112972434A - 一种负载亲水性药物复合纤维膜的制备方法 - Google Patents
一种负载亲水性药物复合纤维膜的制备方法 Download PDFInfo
- Publication number
- CN112972434A CN112972434A CN202110266088.1A CN202110266088A CN112972434A CN 112972434 A CN112972434 A CN 112972434A CN 202110266088 A CN202110266088 A CN 202110266088A CN 112972434 A CN112972434 A CN 112972434A
- Authority
- CN
- China
- Prior art keywords
- drug
- fiber membrane
- polylactic acid
- composite fiber
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Artificial Filaments (AREA)
Abstract
本发明涉及一种负载亲水性药物复合纤维膜的制备方法,属于医药技术领域。本发明主要解决可生物降解聚合物聚乳酸(PDLLA)负载亲水性药物不均匀导致药物突释的问题。包括(1)纤维素纳米晶(NCC)接枝L‑丙交酯改性,其接枝率为0.1‑2.26、接枝聚合物的聚合度为1‑1.45、聚乳酸侧链的重量含量为10%‑55%、聚乳酸的摩尔取代度为0.5‑2.66;(2)利用具有特定支链结构的改性纤维素纳米晶和非结晶聚乳酸制备具有不同微观形貌的载药电纺纤维膜。本发明大大提升了纤维素在聚乳酸基体中的分散均匀程度,从而使得亲水性药物可以均匀的分散在纤维膜中从而缓解药物突释问题。同时提高了力学性能可以满足敷料要求。
Description
技术领域
本发明属于医药技术领域,具体涉及一种负载亲水性药物复合纤维膜的制备方法。
背景技术
对于常规的药物输送系统,包括口服,注射,透粘膜等,药物被输送到全身循环,而不是客观地输送到特定部位。通常,药物被瞬间全部释放,随后随着时间的流逝而迅速清除,导致疾病治疗的效果受到限制。据报道,只有非常少的药物分子被递送到患病区域。开发合适的药物释放系统以实现可持续释放是生物医学进步的基本目标。大量的研究集中于开发具有有效载药量和控释作用的载药材料,从而使药物浓度在治疗窗口内保持较长的时间。
当前人们已经开发出一系列的药物载体用于药物缓释,常用的材料有海藻酸盐、壳聚糖、明胶、蛋白类(胶原、白蛋白)等。但是都存在一定的局限性,比如实际生产中可利用海藻酸盐的溶胀凝胶的特性作为缓释制剂辅料。但是由于这种弱的静电作用力,使其形成的凝胶材料机械稳定性差、持久性差以及扩散速率高。而壳聚糖本身不溶于水,可溶于部分的稀酸中,由于这方面的缺陷使其在生物领域受到一定程度的限制。还有一些药物载体如多孔的二氧化硅、羟基磷灰石、陶瓷材料等,这些材料在体内不可降解。
良好的药物缓释载体应具有较好的生物相容性、生物可降解吸收、一定的力学强度和强度衰减速率、良好的可塑性、高的比表面积和孔隙率、有利于细胞的生长和蛋白的粘附、缓释效果明显等。通过静电纺丝法生产的纳米纤维由于其亚微米级的纤维尺寸和孔径,高比表面积以及结构可控制的特性(例如,仿生细胞外基质)而被用于制备药物载体。
聚乳酸良好的生物相容性和生物降解性,及降解产物的矿化作用和可代谢性,使得其成为短期医用生物材料中最具吸引力的聚合物之一。聚乳酸是可直接与生物体液接触的材料,因此在外科手术、药物控制释放、骨骼材料、眼科材料、组织工程材料等生物医学领都有应用。但聚乳酸的疏水性使其在加载亲水性药物时存在缺陷,聚乳酸加载亲水性药物容易使得药物被团聚在材料表面,突释现象明显,而亲水性材料搭载亲水性药物时,材料和药物都会降解导致无缓释效果;并且聚乳酸耐热性能差、脆性等典型缺陷也限制了它的广泛应用。因此需要增强聚乳酸材料的热稳定性、力学强度和搭载亲水性药物均匀性,从而使其得到更广泛的应用。
纤维素纳米晶是一种十分优异的复合材料纳米增强材料,因其具有纳米尺寸、优异的力学性能、易于化学修饰、低密度以及可再生、可降解并具有良好的生物相容性等特点而备受关注。其来源很广,如木材、剑麻、芦苇以及诸如油茶果壳、麦秆、玉米杆、大豆秸秆等农作物废弃物,都可制备纤维素纳米晶。并且纤维素纳米晶已经被证明可以有效的增强聚乳酸。由于纤维素纳米晶和聚乳酸材料的相容性太差导致增纤维素纳米晶容易在聚乳酸基体中团聚,从而力学和热力学性能提升不大,也不利于均匀的加载亲水性药物。因此必须先对纤维素纳米晶进行改性。而本方法的优势是通过在纤维素表面接枝聚乳酸的单体L-丙交酯来改善与聚乳酸的界面相容性,可以更好的提高两者的界面相容性进而改善聚乳酸作为药物载体的一些缺陷。
本方法通过静电纺丝制备了纤维素纳米晶增强的串珠复合纤维膜。可用于均匀加载亲水型药物双氯芬酸钠,制备载药串珠纤维。
发明内容
本发明的目的是提供一种负载亲水性药物双氯芬酸钠复合纤维膜的制备方法,该方法解决了聚乳酸与亲水性药物相容性差,药物突释明显的问题,同时也增强了聚乳酸纤维膜的力学性能。所得的载药纤维膜可广泛用于镇痛辅料,具有良好的应用前景。
一种负载亲水性药物复合纤维膜的制备方法它是由NCC-LA、PDLLA和双氯芬酸钠组成,其中NCC-LA/PDLLA的质量百分数为1~10%,双氯芬酸钠/PDLLA的质量百分数为0.1~50%。
本发明的上述技术目的是通过以下技术方案得以实现的:
1.表面接枝L-丙交酯纤维素纳米晶的制备:
(1)将N-甲基咪唑和烯丙基氯分别加入装有磁力搅拌和冷凝器的三颈烧瓶中。氮气保护,60℃下磁力搅拌6小时,得到淡黄色液体。自然冷却到室温,用乙醚萃取去除未反应的N-甲基咪唑,低温旋蒸除去多余的烯丙基氯。将得到的淡黄色粘性离子液体在60℃下真空中干燥48小时用于去除水分。
(2)将纤维素纳米晶溶液进行冷冻干燥,得到白色固体NCC,放入冰箱中备用。将NCC溶于离子液体中。氮气保护,一定温度下搅拌溶解,直到形成透明溶液。加入L-丙交酯和辛酸亚锡。氮气保护下将温度升高,L-丙交酯与NCC在离子液体中进行开环接枝聚合,反应36小时后进行冷却。
(3)在过量的乙醇中除去未反应的L-丙交酯、残留的催化剂和离子液体。沉淀进行干燥,得到白色粉末。将接枝聚合物与二氯甲烷在室温下搅拌72小时。洗涤三次以除去均聚的L-丙交酯。沉淀用更多的二氯甲烷洗涤,用乙醇接触几滴滤液,直到无沉淀生成。
所述N-甲基咪唑和烯丙基氯的摩尔比例为1:1~3,纤维素纳米晶与L-丙交酯的质量比例为1:1~10,纤维素纳米晶与离子液体的质量比为1:40~60。
2.载药复合纤维膜的制备:
(1)将改性纤维素纳米晶、非结晶型聚乳酸和双氯芬酸钠溶于二氯甲烷和N-N二甲基甲酰胺混合溶剂中。
(2)将混合溶剂转移到注射器中,用静电纺丝机进行纺丝,制得均匀载药复合纤维膜。
所述二氯甲烷与N-N二甲基甲酰胺的体积比为1:0.1-1,纺丝过程中环境相对湿度为5-80%,纺丝距离10-20cm,纺丝电压为10-20KV。
3.与现有技术相比,本发明的有意效果是:
(1)本发明制备了具有特定支链结构的纤维素纳米晶,并与非晶聚乳酸进行复合,提高了纤维素纳米晶与聚乳酸基体的相容性。利用静电纺得到了纤维素纳米晶分散均匀的聚乳酸复合纳米纤维膜,并表现出良好的力学性能。
(2)本发明制备的复合纳米纤维膜由于提高了混纺亲水性药物分散性,并结合了非结晶聚乳酸良好的降解性能,使其对亲水性药物双氯芬酸钠表现出良好的缓释效果。
(3)本发明制备的双氯芬酸钠载药复合纤维膜用作医用敷料,该敷料能够镇痛并具有柔韧性,能够承受外力的作用,适用于关节等活动部位。
附图说明:
图1静电纺丝所配置溶液图,其中左侧为PDLLA/NCC-LA溶液,右侧为PDLLA/NCC溶液。
图2纤维素、纤维素接枝L-丙交酯和聚乳酸的红外表征图。
图3纯PDLLA纤维膜、PDLLA/NCC纤维膜和PDLLA/NCC-LA纤维膜的热重分析图
图4纯PDLLA纤维膜、PDLLA/NCC纤维膜和PDLLA/NCC-LA纤维膜的力学测试图
图5PDLLA/NCC-LA/双氯芬酸钠串珠载药纤维膜和元素分布图。
图6不同载药纤维药物缓释图
具体实施方式
下面结核具体的实施方式和附图来对本发明的技术方案做进一步的限定,应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1:
1.纤维素纳米晶接枝L-丙交酯的制备
将N-甲基咪唑(27.37g,0.33mol)和烯丙基氯(30.61g,0.4mol)分别加入装有磁力搅拌和冷凝器的三颈烧瓶中。氮气保护,60℃下磁力搅拌6h,得到淡黄色液体。自然冷却到室温,用乙醚萃取去除未反应的N-甲基咪唑,低温旋蒸除去多余的烯丙基氯。将得到的淡黄色粘性离子液体在60℃下真空中干燥48h,收率为89%,得到离子液体。
将纤维素纳米晶(NCC)溶液进行冷冻干燥,得到白色固体,放入冰箱中备用。将5g的NCC溶于50g的离子液体中。氮气保护,80℃下搅拌溶解,直到形成透明溶液。加入5g的L-丙交酯和0.1wt%的辛酸亚锡。氮气保护下将温度升到130℃,L-丙交酯与NCC在离子液体中进行开环接枝聚合。反应36h后进行冷却,在过量的乙醇中除去未反应的L-丙交酯、残留的催化剂和离子液体。沉淀进行干燥,得到白色粉末。将1g的接枝聚合物与50ml的二氯甲烷在室温下搅拌72h。洗涤三次以除去均聚的L-丙交酯。沉淀用更多的二氯甲烷洗涤,用乙醇接触几滴滤液,直到无沉淀生成。将产物真空干燥备用。
2.纺丝溶液与载药纤维的制备
配制N-N二甲基甲酰胺和二氯甲烷的混合溶剂,其中N-N二甲基甲酰胺和二氯甲烷的体积比为1:2;
称取一定质量的非结晶型聚乳酸倒入混合溶剂中,分别配制六份相同的溶液,其中非结晶型聚乳酸的含量为溶液总质量的10%,编号为①②③④⑤⑥。
在②号溶液中加入PDLLA质量分数5%的NCC-LA,③号溶液中加入PDLLA质量分数5%的NCC,④加入药物双氯芬酸钠,⑤号溶液中加入PDLLA质量分数5%的NCC-LA的同时加入药物DCF。其中药物的质量与PDLLA/NCC-LA的质量比为1:5。(3)静电纺丝制备PDLLA/NCC和PDLLA/NCC-LA光滑载药纤维膜
将纺丝液吸入5ml注射器中,在温度28℃、湿度45%、接收距离15cm、推速1.4ml/h、电压为+15KV和-3KV的条件下进行静电纺。
3.载药纤维膜药物释放的评价
(1)PBS缓冲液的制备
称取8g NaCl、0.2g KCl、3.64g Na2HPO4·12H2O、0.24gKH2PO4溶于超纯水中,用1L的容量瓶进行定容并将PH调至7.4。
a.标准曲线的制备
首先配制了浓度分别为5mg/L、10mg/L、15mg/L、20mg/L、25mg/L、30mg/L、35mg/L、40mg/L、45mg/L和50mg/L等10种DCF/PBS标准溶液,用紫外分光光度计测试其吸光度并绘制标准曲线。
b.药物释放
剪取面积为9cm2载药纳米纤维膜,放入玻璃瓶中,加入100ml的PBS缓冲液并密封,放置在37℃、震荡速度为80r/min的恒温摇床中。在设定的时间上取出3ml缓释液用来测量释放的TCH含量,测试后将溶液倒回原由缓释液。取出的缓释液样品在紫外光可见光分光光度计下,276nm处测量其吸光度值。根据对应的标准曲线计算药物的浓度、释放量和累计释放率。
释放效果如图6所示,PDLLA载药纤维突释现象明显,而PDLLA/NCC-LA载药光滑纤维和串珠纤维有效的改善了药物突释且缓释时间更长。
实施例2:
静电纺丝制备PDLLA/NCC-LA载药光滑纤维膜的制备
其它步骤同实施例1,将纺丝液吸入5ml注射器中,在温度28℃、湿度75-80%、接收距离15cm、推速1.4ml/h、电压为+15KV和-3KV的条件下进行静电纺。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其它的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种负载亲水性药物复合纤维膜,其组成包括:生物可降解聚合物聚乳酸、表面改性的纤维素纳米晶和亲水性药物。
2.如权利1所述的一种负载亲水性药物复合纤维膜,其特征在于:所述生物可降解聚合物为非结晶型右旋聚乳酸与左旋聚乳酸的共聚物(PDLLA)。
3.如权利1所述的一种负载亲水性药物复合纤维膜,其特征在于:所述表面改性的纤维素纳米晶为纤维素纳米晶表面接枝L-丙交酯(NCC-LA),其接枝率为0.1-2.26、接枝聚合物的聚合度为1-1.45、聚乳酸侧链的重量含量为10%-55%、聚乳酸的摩尔取代度为0.5-2.66。
4.如权利1所述的一种负载亲水性药物复合纤维膜,其特征在于:所述亲水性药物为双氯芬酸钠。
5.如权利1所述的一种负载亲水性药物复合纤维膜,其特征在于:所述药物复合纤维膜的形貌为串珠纤维组成。
6.如权利1所述的一种负载亲水性药物复合纤维膜的制备方法,包含如下步骤:(1)纤维素纳米晶接枝L-丙交酯改性
首先将纤维素纳米晶溶液进行冷冻干燥,得到白色固体NCC,放入冰箱中备用;将NCC溶于离子液体中;氮气保护,一定温度下搅拌溶解,直到形成透明溶液;加入L-丙交酯和辛酸亚锡;氮气保护下将温度升高反应一段后进行冷却,在过量的乙醇中除去未反应的物质;沉淀后进行干燥,得到白色粉末;将接枝聚合物与二氯甲烷在室温下搅拌一段时间;洗涤三次,淀用更多的二氯甲烷洗涤,用乙醇接触几滴滤液,直到无沉淀生成;将产物真空干燥备用;
(2)载药复合纤维膜的制备方法
将改性纤维素纳米晶、非结晶型聚乳酸和双氯芬酸钠溶于混合有机溶剂,将混合溶剂用注射器吸出,在静电纺丝机进行纺丝,制得载药串珠复合纤维膜。
7.根据权利要求6所述的一种负载亲水性药物复合纤维膜的制备方法,其特征在于:所述步骤(1)所用纤维素纳米晶与L-丙交酯的质量比例为1:1~10,反应环境无氧,纤维素纳米晶在溶液中溶解温度为60-90℃,接枝温度为120-150℃。
8.根据权利要求6所述的一种负载亲水性药物复合纤维膜的制备方法,其特征在于:所述步骤(2)所用溶剂为混合溶剂,其中二氯甲烷与N-N二甲基甲酰胺的体积比为1:0.1-1,所用二氯甲烷可由三氯甲烷、丙酮、二氯乙酸、丁酮等非结晶型聚乳酸的良溶剂替换,N-N二甲基甲酰胺可由N-N二甲基乙酰胺替代。
9.根据权利要求6所述的一种负载亲水性药物复合纤维膜的制备方法,其特征在于:所述步骤(2)所用非结晶型聚乳酸与修饰后纤维素纳米晶的质量比为100:1~10,非结晶型聚乳酸与双氯芬酸钠的质量比为100:0.1~50,所用DCF可由其它亲水性药物替换,如头孢呋辛、头孢替安等。
10.根据权利要求6所述的一种负载亲水性药物复合纤维膜的制备方法,其特征在于:所述步骤(2)中静电纺丝过程中所用溶剂体系为两相体系,纺丝过程中环境相对湿度为5-40%,纺丝距离为10-20cm,纺丝电压为10-20KV。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110266088.1A CN112972434A (zh) | 2021-03-11 | 2021-03-11 | 一种负载亲水性药物复合纤维膜的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110266088.1A CN112972434A (zh) | 2021-03-11 | 2021-03-11 | 一种负载亲水性药物复合纤维膜的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112972434A true CN112972434A (zh) | 2021-06-18 |
Family
ID=76336395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110266088.1A Pending CN112972434A (zh) | 2021-03-11 | 2021-03-11 | 一种负载亲水性药物复合纤维膜的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112972434A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110196094A1 (en) * | 2010-02-11 | 2011-08-11 | Fpinnovations | Nanocomposite biomaterials of nanocrystalline cellulose (ncc) and polylactic acid (pla) |
CN102276843A (zh) * | 2011-06-14 | 2011-12-14 | 东华大学 | 一种无溶剂固–固相变储能材料的制备方法 |
CN102423506A (zh) * | 2011-12-09 | 2012-04-25 | 东华大学 | 一种用于治疗牙周炎的药物缓释纳米纤维膜及其制备方法 |
CN102772828A (zh) * | 2012-07-10 | 2012-11-14 | 东华大学 | 一种自调节高载药纳米纤维药物缓释膜及其制备方法 |
CN104292439A (zh) * | 2014-10-07 | 2015-01-21 | 桂林理工大学 | 剑麻纤维素纳米晶须/聚乳酸生物复合材料的制备方法 |
CN106400507A (zh) * | 2016-09-26 | 2017-02-15 | 桂林理工大学 | 一种水性有机硅修饰剑麻纤维表面制备防水材料的方法 |
US20190055324A1 (en) * | 2015-10-27 | 2019-02-21 | The Research Foundation For The State University Of New York | Method for preparing modified nanocrystalline cellulose |
CN110130094A (zh) * | 2019-04-25 | 2019-08-16 | 东华大学 | 活化植物纤维及其制备方法和在聚乳酸复合材料中的应用 |
-
2021
- 2021-03-11 CN CN202110266088.1A patent/CN112972434A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110196094A1 (en) * | 2010-02-11 | 2011-08-11 | Fpinnovations | Nanocomposite biomaterials of nanocrystalline cellulose (ncc) and polylactic acid (pla) |
CN102276843A (zh) * | 2011-06-14 | 2011-12-14 | 东华大学 | 一种无溶剂固–固相变储能材料的制备方法 |
CN102423506A (zh) * | 2011-12-09 | 2012-04-25 | 东华大学 | 一种用于治疗牙周炎的药物缓释纳米纤维膜及其制备方法 |
CN102772828A (zh) * | 2012-07-10 | 2012-11-14 | 东华大学 | 一种自调节高载药纳米纤维药物缓释膜及其制备方法 |
CN104292439A (zh) * | 2014-10-07 | 2015-01-21 | 桂林理工大学 | 剑麻纤维素纳米晶须/聚乳酸生物复合材料的制备方法 |
US20190055324A1 (en) * | 2015-10-27 | 2019-02-21 | The Research Foundation For The State University Of New York | Method for preparing modified nanocrystalline cellulose |
CN106400507A (zh) * | 2016-09-26 | 2017-02-15 | 桂林理工大学 | 一种水性有机硅修饰剑麻纤维表面制备防水材料的方法 |
CN110130094A (zh) * | 2019-04-25 | 2019-08-16 | 东华大学 | 活化植物纤维及其制备方法和在聚乳酸复合材料中的应用 |
Non-Patent Citations (5)
Title |
---|
CHUNJIANG XU,等: "Polylactide/acetylated nanocrystalline cellulose composites prepared by a continuous route: A phase interface-property relation study", 《CARBOHYDRATE POLYMERS》 * |
ZHENBO CAO,等: "Fluorescence Anion Chemosensor Array Based on Pyrenylboronic Acid", 《FRONTIERS IN CHEMISTRY》 * |
刘兆麟: "静电纺串珠纤维形貌结构及载药性能的研究进展", 《材料导报》 * |
曹阳: "改性纤维素增强聚乳酸电纺膜的结构调控及其应用研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
肖舒: "4-二甲氨基吡啶催化合成纤维素——聚乳酸接枝共聚物的研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Advances in electrospinning of natural biomaterials for wound dressing | |
Nezhad-Mokhtari et al. | A review on the construction of hydrogel scaffolds by various chemically techniques for tissue engineering | |
Li et al. | Biological properties of dialdehyde carboxymethyl cellulose crosslinked gelatin–PEG composite hydrogel fibers for wound dressings | |
Yan et al. | Injectable in situ forming poly (l-glutamic acid) hydrogels for cartilage tissue engineering | |
US9907637B2 (en) | Modular bioresorbable or biomedical, biologically active supramolecular materials | |
CN105473622B (zh) | 用于制造成形的交联的透明质酸产物的方法 | |
Cascone et al. | Effect of chitosan and dextran on the properties of poly (vinyl alcohol) hydrogels | |
Panzavolta et al. | Electrospun gelatin nanofibers: Optimization of genipin cross-linking to preserve fiber morphology after exposure to water | |
US11168183B2 (en) | Method for the production of hydrogel comprising chitosan and negatively charged polyelectrolytes, and cellular, porous material resulting from said hydrogel | |
Ma et al. | Synthesis and characterization of injectable self-healing hydrogels based on oxidized alginate-hybrid-hydroxyapatite nanoparticles and carboxymethyl chitosan | |
US20110262489A1 (en) | Hyaluronic acid cryogel - compositions, uses, processes for manufacturing | |
CN104524643A (zh) | 含有埃洛石纳米管载药型引导组织再生膜及其制备方法 | |
WO2008067655A1 (en) | Biocompatible hydrogel-based scaffolds | |
US20070248642A1 (en) | Foam and use thereof | |
EP3991792A1 (en) | Transplantation device using chemically crosslinked alginic acid | |
Zhang et al. | Photopolymerizable chitosan hydrogels with improved strength and 3D printability | |
Hassanzadeh et al. | Development and biocompatibility of the injectable collagen/nano-hydroxyapatite scaffolds as in situ forming hydrogel for the hard tissue engineering application | |
CN112494463B (zh) | 一种小檗碱/矿化胶原复合膜及其制备方法和应用 | |
Liu et al. | Biomedical applications of bacterial cellulose based composite hydrogels | |
Ross et al. | Novel 3D porous semi-IPN hydrogel scaffolds of silk sericin and poly (N-hydroxyethyl acrylamide) for dermal reconstruction | |
Zhang et al. | pH-responsive injectable polysaccharide hydrogels with self-healing, enhanced mechanical properties based on POSS | |
Wu et al. | Mechanical properties and permeability of porous chitosan–poly (p-dioxanone)/silk fibroin conduits used for peripheral nerve repair | |
Kongprayoon et al. | Bio-derived and biocompatible poly (lactic acid)/silk sericin nanogels and their incorporation within poly (lactide-co-glycolide) electrospun nanofibers | |
Madhumanchi et al. | Polymeric biomaterials | |
Hajiabbas et al. | Hybrid silk fibroin–gelatin nanofibrous sheet for drug delivery and regenerative medicine: In‐vitro characterization and controlled release of simvastatin/protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 530001 No.15 Anji Avenue, Nanning, Guangxi Zhuang Autonomous Region Applicant after: GUILIN University OF TECHNOLOGY Address before: 541004 the Guangxi Zhuang Autonomous Region Guilin City Seven Star District Building Road No. 12 Applicant before: GUILIN University OF TECHNOLOGY |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210618 |